Sections & Research
- Varian Medical Systems - a Siemens Healthineers company
- Comprehensive Cancer Center Freiburg (Freiburg Cancer Center)
- German Consortium for Translational Cancer Research (DKTK), an initiative of excellence by the BMBF (Federal Ministry of Education and Research) and the federal states; partner sites: Freiburg, Heidelberg, Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Munich, Tübingen
- Harvard Medical School/Massachusetts General Hospital, Boston, USA (Thomas Bortfeld)
- Edwin L. Steele Laboratory for Tumor Biology, Boston, USA (Dan Duda)
- Ohio State University (OSU), Columbus, USA (Arnab Chakravarti)
- Karolinska Institute, Stockholm, Sweden (Iuliana Toma-Dasu)
- Istituto Scientifico San Raffaele (IRCCS), Milan, Italy (Maria Picchio; Arturo Chiti)
- University of Oxford, United Kingdom (Gillies McKenna, Amato Giaccia)
- University Hospital Zurich, Switzerland (Matthias Guckenberger)
- Sapienza University of Rome AOU Sant’Andrea, Italy (Mattia Osti)
- Medical School of Nanjing University, affiliated with Drum Tower Hospital, China (Xuefeng Qiu)
- Maastricht University, Netherlands (Dirk de Ruysscher)
- University of Leuven, Belgium (Karin Haustermans)
- Various industry partners
Studies currently recruiting participants
You can find the latest information about our ongoing studies at the following link
High-dose chemoradiotherapy (75 Gy) with 2 cycles of bevacizumab to manage adverse effects in glioblastoma
Contact:
Phase I clinical trial to evaluate a personalized mRNA-based cancer vaccine for glioblastoma, with a focus on safety, tolerability, and immune response.
Contact:
Circulating Free Extracellular Vesicles in Meningioma Patients Following Radiotherapy for Liquid Biopsy
Contact:
De-escalation of adjuvant radio(chemo)therapy for HPV-positive head and neck squamous cell carcinomas.
A Phase I study to reduce late toxicity.
Contact:
Effects of Speech Therapy on Dysphagia and Trismus in Patients with Head and Neck Tumors
Contact:
FDG-PET-guided small-volume and accelerated chemoradiotherapy with or without durvalumab maintenance therapy for locally advanced NSCLC
Contact:
Prospective Phase II study to investigate the systemic effects and efficacy of the combination of radiation therapy and immunotherapy in metastatic NSCLC, particularly with regard to potential off-target effects
Contact:
Prospective, randomized Phase II study to evaluate induction immunochemotherapy followed by surgery or definitive chemoradiotherapy and subsequent durvalumab maintenance therapy in patients with Stage IIIA/B NSCLC.
Contact:
Prospective, single-center, non-interventional study to investigate the efficacy, tolerability, and predictive biomarkers of a combination of hyperthermia and hypofractionated re-irradiation in locally recurrent breast cancer.
Contact:
International, randomized Phase III trial evaluating preoperative versus postoperative radiation therapy following neoadjuvant chemotherapy in high-risk breast cancer
Contact:
Multicenter, randomized Phase III trial evaluating image-guided focal dose escalation using stereotactic body radiation therapy (SBRT) compared with standard moderately hypofractionated radiation therapy for primary prostate cancer
Recruitment completed
Contact:
Molecular characterization of prostate cancer tissue for risk stratification of patients with primary prostate cancer following PSMA-PET-based staging and radiation therapy
Contact:
A randomized Phase II trial in patients with oligoprogressive metastatic prostate cancer currently receiving systemic therapy, to evaluate localized ablative radiotherapy compared with continued or adjusted standard systemic therapy alone.
Contact:
Completed studies
Short-course radiotherapy versus chemoradiotherapy followed by consolidation chemotherapy and selective organ preservation for patients with MRI-defined intermediate- and high-risk rectal cancer: A randomized Phase III trial by the German Rectal Cancer Study Group
Recruitment completed
Prospective, multicenter biomarker study in patients with head and neck tumors to analyze predictive molecular markers in the context of radiation therapy.
Recruitment completed
A randomized, multicenter Phase II study in patients with resectable Stage III NSCLC to evaluate induction chemotherapy and chemoradiotherapy with or without durvalumab, followed by surgery or a chemoradiotherapy boost, as well as durvalumab consolidation.
Recruitment completed
Evaluation of 18F-MISO-PET-detectable changes in the extent and distribution of hypoxic subvolumes in head and neck tumors in patients undergoing radio(chemo)therapy. Prospective Phase II study
Recruitment completed
A randomized, double-blind, international, multicenter Phase III study to evaluate the antitumor efficacy and safety of HLX10 (recombinant humanized anti-PD-1 monoclonal antibody for injection) compared to placebo in combination with chemotherapy (carboplatin/cisplatin + etoposide) and concurrent radiotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).
Recruitment completed
A prospective, multicenter Phase II study in patients with primary prostate cancer, investigating the image-guided identification of intraprostatic tumor masses using mpMRI and PSMA-PET/CT, and focal dose escalation via external beam radiation therapy or HDR brachytherapy in combination with whole-gland irradiation.
Recruitment completed
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Recruitment completed
An open-label, randomized Phase II study of nivolumab to evaluate the efficacy and safety of a single dose prior to, concurrent administration during, and subsequent 12-month maintenance therapy in patients with advanced resectable head and neck squamous cell carcinoma following surgery.
Recruitment completed
Implementation of mobile health tools and artificial intelligence for personalized planning and monitoring of radiation therapy for prostate cancer
Recruitment completed
Radiation therapy in combination with pembrolizumab in patients with persistent PSA levels or biochemical recurrence following radical prostatectomy for prostate cancer
Recruitment completed
Radiochemotherapy with or without durvalumab for the treatment of anal cancer: a randomized, multicenter Phase II trial
Recruitment completed